<DOC>
	<DOCNO>NCT01924156</DOCNO>
	<brief_summary>The aim Phase I/II study evaluate safety efficacy dendritic cell ( DC ) vaccine combine cytokine-induced killer ( CIK ) cell patient renal cell carcinoma . Experimental recombinant adenovirus-transfected DC , engineer express MUC1 Survivin use DC-based immunotherapy . Based result previously perform preclinical study DC vaccine combine CIK cell , investigator plan perform clinical trial .</brief_summary>
	<brief_title>DC Vaccine Combined With CIK Cells Patients With Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Age &gt; 18 year time consent Histopathologically confirm diagnosis renal cell carcinoma Received standardize treatment renal cell carcinoma Interval last standardized treatment DC/CIK treatment â‰¥ 4weeks KPS ( Karnofsky performance scale ) &gt; 60 Patient 's write informed consent Predicted survival &gt; 3 month No severe viral bacterial infection Receiving chemotherapy , radiotherapy therapy Patients malignancies infectious disease Pregnant breastfeed patient Currently participate another clinical trial Unfit participate clinical trial investigator ' opinion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>